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The tumor microenvironment contains a complex mix of
cell types that can modulate the anti-tumor immune
response. In the present study we performed a characteri-
zation of tumor-associated B cells, aimed at understand-
ing the biological implications of B cell infiltration in
metastases of melanoma patients. We performed a com-
parative analysis between B cells present in peripheral
blood (PBMC) of metastatic melanoma patients and
those present in single cell suspensions prepared from
metastatic lesions (FrTu) of the same patients. Flow cyto-
metry analysis of these populations showed that the
mean B-to-T cell ratio was 5-fold higher in FrTu than in
PBMC (p= 0.004, n= 14). Spectratyping of immunoglobu-
lin genes present in FrTu-B revealed a profile that is
compatible with an oligoclonal population, as opposed to
the polyclonal distribution observed in PBMC-B. Next,
we analyzed the expression of 511 genes related to
immune cell function in PBMC-B and FrTu-B cells of
seven patients. Using a digital platform for direct quanti-
tation of mRNA molecules, we identified forty genes that
were differentially expressed (fold change>2, p<0.05),
including cytokines (IL6, TNF), death receptors (FAS),
differentiation makers (SELL) and transcription factors
(BCL6, IKZF1, ETS1, ZEB1, NFKB2), among others.
In addition, we analyzed mRNA expression of activation-
induced cytidine deaminase (AICDA), an enzyme
induced upon B cell activation. We found that AICDA
expression was significantly higher in FrTu-B than in
PBMC-B cells (p=0.03, n=6). Basal expression of HLA-
DR in both FrTu- and PBMC-B cell, as well as induced
CD86 expression upon stimulation, suggest that B cells
may act as antigen presenting cells and contribute to the
initiation of a T cell-based anti-tumor immune response.
Our results show that melanoma-associated B cells are
distinct from peripheral blood B cells in terms of
abundance, clonality and gene expression patterns. Our
current efforts are focused on the analysis of FrTu-B cell
specificity by lymphocyte display of single chain-variable
fragment libraries derived from FrTu-B, with special
interest in the identification of antibodies that recognize
tumor-specific neoantigens resulting from somatic muta-
tions, for their potential use in personalized chimeric
antigen receptor-based adoptive immunotherapies.
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